“Arise, take up thy bed,” Christ commanded a paralyzed man, according to the Gospel of Matthew. The man “arose and departed.” Healing a paralytic is miraculous… But it may soon become an everyday miracle of science, rather than a rare miracle of faith.
In April 2011, the Washington Post reported that the first patient to receive a human embryonic stem-cell treatment for paralysis from a spinal-cord injury had regained some feeling in his legs.
Timothy Atchinson, a 21-year-old nursing student in Alabama, was paralyzed from the waist down in a car accident in September 2010. He quickly accepted an offer to be the initial participant in the world’s first clinical trial using human embryonic stem cells. Now after months of not feeling or not being able to move his body below his chest, Atchison claimed he had begun to get some very slight sensation: He could feel relief when he lifted a bowling ball off his lap and discern discomfort when he pulled on hairs on some parts of his legs. He had also strengthened his abdomen.
This miraculous medical breakthrough was fascinating to me, not simply because the story itself is amazing, but also because I witnessed the genesis of the research that made it possible.
The treatment emerged from the laboratory of Hans Keirstead, a neurobiologist with the Sue & Bill Gross Stem Cell Research Center at UC Irvine. While Dr. Keirstead was busy making his groundbreaking discovery in his lab, I was conducting a completely different sort of stem cell research in a nearby lab at UCI.
UCI has a robust stem cell research program that has received more than $52 million from the California Institute for Regenerative Medicine. A four-story building dedicated to stem cell research broke ground in 2010. It houses the stem cell center, dozens of laboratory-based and clinical researchers, a stem cell techniques course, a master’s program in biotechnology with an emphasis on stem cell research, and programs and activities for patients and public education.
Neurobiologist Hans Keirstead was very well-known and respected at UCI, even before his groundbreaking research project. He had been trying for years to find a way to use human embryonic stem cells to restore movement in people who have suffered spinal injuries. In 2005, he published a cutting-edge report in the Journal of Neuroscience entitled “Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury.”
In other words, he enabled paralyzed rats to walk again.
The therapy he developed utilizes embryonic stem cells destined to become spinal cord cells called oligodendrocytes. These are the building blocks of myelin, the biological insulation for nerve fibers that is critical for maintaining electrical conduction in the central nervous system. When myelin is stripped away, through injury or disease, paralysis can occur.
The study showed that a week after test rats with 100 percent walking ability suffered neck spinal cord injuries, some received the stem cell treatment. The walking ability of those that didn’t get the treatment degraded to 38 percent. The walking ability of the treated rats, however, was restored to 97 percent.
When I started to work at UCI, two years after Keirstead published his initial findings, his research had advanced significantly. He had shown, for example, that the therapy using human embryonic stem cells was not harmful to the rats, and he was reviewing the practical considerations and risks that must be addressed before human treatments could begin.
By the summer of 2010, the FDA approved the Embryonic Stem Cell-Based Therapy For Patients With Acute Spinal Cord Injury. This trial started in Oct 2010…
… And so did the controversy.
Most of us at UCI were intrigued by Keirstead’s research…especially when it progressed from rats to humans. At that moment, the buzz among us was, “They’re going to try it on humans! Can you believe it?” But in the broader scientific community, many folks were dubious and dismissive, if not completely alarmed.
Arthur Caplan, a bioethicist at the University of Pennsylvania and a defender of stem-cell therapies famously bashed the trial saying that it was poorly designed. “This is nuts and hugely risky,” says Caplan. “The animal studies are not adequate to justify the trial. Those studies provide too little proof of safety and Keirstead’s original findings in rats offer thin evidence that people will be helped.”
One year into trial, however, none of the 10 patients have experienced any adverse reactions from the treatment, although a few “mild” adverse reactions were reported from a drug used to suppress the patients’ immune responses.
Keirstead has said the initial reports from the paralyzed Timothy Atchinson are exciting, but anecdotal and not scientifically verified. The formal outcome of this trial won’t be known until two years after the last of the ten patients receives the therapy.
Meanwhile, other trials are ongoing using adult-induced pluripotent stem cells to repair spinal cord injuries, rather than embryonic stem cells. No matter the ultimate results of these particular stem cell trials, stem cell therapies are on the threshold of making truly miraculous cures an everyday event.
Severine Kirchner, PhD,for The Daily Reckoning
After she obtained her PhD in nutrition and Food Science at the University of Bordeaux in 2004, Severine Kirchner left her native France to work as a molecular and cellular biologist in the United-States. Her successive appointments as a research associate for the University of Medicine and Dentistry of New Jersey and the University of California Irvine allowed her to conduct research on the metabolic disorders diabetes and obesity. For more than 10 years she has had a keen interest in new technologies such as transcriptomics and stem cell biology that she studied firsthand in the lab.
Just think, two years after getting rid of Baby Bozo Bush, medicane is again making progress. Just one election and poof!, no more psuedo “christian” ethics. No more dark ages mentality. Now just get rid of the tar baby in the white house.
How do they scientifically verify that the progress Timothy Atchinson has made is a result of the stem cell therapy?
Vous etes tres jolie, Severine!
4 more yrs of “Tar Baby!” RU kiddin me? And that Pretty Boy Cracker fr Bain is gonna solve all your problems! Get Real… HT2all *S*
A human being is terminated, so another can walk.
This is plain wrong. An evil means can never justify a positive end.
Right on JC
Severine Kirchner? This is my name, I live in Berlin and out of boredom
I researched for my name,
funny, I did not think?
When it comes to the stock market, October gets a bad rap. It's true, there have been some major crashes in October (ahem... Black Monday, Black Tuesday, etc.) but on a shorter timeline this month hasn't been nearly as bad as you might think. Today, Greg Guenthner offers an optimistic look at the month investors love to hate. Read on...
Big government doesn't come cheap. And right now the U.S. government is one of the biggest in history. So far the budget writers have been able to move money around to keep the machine moving. But as Byron King points out, that will soon become much more difficult. Read on for the full story...
In the late '90s, financial TV personalities like Jim Cramer became mega stars - often drawing more ratings the ESPN. But that was over 15 years ago... That couldn't happen again, could it? Today, Wayne Mulligan details the new flock of personalities that are set to cash-in on a different kind of investment boom. Read on...
Being a "whistleblower" is no easy task. Regardless of whom you're blowing the whistle on, there's bound to be a fair amount of risk involved... and that's especially true if you're going after the "powers that be." But there's more to it than that... And as Chris Campbell explains, none of it matters if you can't protect yourself. Read on...
As conflict with ISIS looms, the Pentagon appears to be in a pickle... They've got all kinds of things on their "wish list", and they're not likely to get all of them. But they may have found a loophole, and that could mean big bucks for a handful of investors who know where to look. Peter Coyne explains...
Last week was a rough one for most of the world's markets. Investors saw red almost everywhere they looked. And that's got a few media outlets ready to declare a top in stocks. Greg Guenthner explains why this line of thinking could be dangerous... and why, if you follow it, you could be doing your portfolio a disservice. Read on...